表紙
市場調査レポート

MediPoint:冠動脈ステント - 南米地域 (ブラジル) の分析・市場予測

MediPoint: Coronary Stents - SA Analysis and Market Forecasts

発行 GlobalData 商品コード 325986
出版日 ページ情報 英文 367 Pages
即納可能
価格
本日の銀行送金レート: 1USD=106.71円で換算しております。
Back to Top
MediPoint:冠動脈ステント - 南米地域 (ブラジル) の分析・市場予測 MediPoint: Coronary Stents - SA Analysis and Market Forecasts
出版日: 2014年11月30日 ページ情報: 英文 367 Pages
概要

世界の冠動脈ステント市場はダイナミックな2桁市場ですが、革新的技術を持った多くの企業が参入し、飽和状態となっています。低侵襲性技術の開発に伴う心血管インターベンション分野の急速な発展が多くの治療への応用の可能性を広げています。

当レポートでは、世界および南米地域 (ブラジル) の冠動脈ステントの市場について調査し、疾患および治療の概要とアンメットニーズ、市場成長への各種影響因子および市場機会の分析、技術開発の動向と競合的評価、パイプラインの動向、主要企業のプロファイル、市場規模の推移と予測などをまとめています。

第1章 目次

第2章 イントロダクション

第3章 産業概要

  • 疾患概要
  • 臨床転帰
    • 治療ガイドライン
    • 治療モダリティ
  • 手術の動向
    • ブラジル
  • 市場へのアクセス
    • 法規制上の手続き
    • 医師による意思決定プロセス
    • 共同購入組織 (GOP:Group Purchasing Organizations) の役割
    • 臨床データの不足
    • 地域レベルのコントロール
    • コストの考察
    • 償還動向
  • 法規制上の課題・リコール
  • M&A・主な提携
  • 冠動脈疾患の経済的影響
    • ブラジル
  • 冠動脈疾患の治療コスト

第4章 アンメットニーズ

  • 特異的病変におけるよりよい臨床転帰へのニーズ
  • バルーン血管形成の失敗のメカニズムの除去
  • ステント留置後の心筋梗塞
  • 永久的ポリマーの除去
  • ステント内再狭窄
  • ステント内ステントの処置
  • 長期DAPT (抗血小板薬2剤併用療法)
  • 均一な薬剤分布の不足
  • ステントの内皮化遅延
  • 陰性血管リモデリング
  • 特定患者集団への効果的な治療の必要性
  • ?冠動脈バイパス術の合併症への対処

第5章 市場機会の分析

  • ステントデザインおよびプラットフォームの改善
  • ハイブリッドステントシステム
  • 難しい冠動脈症状に対する有効な治療法
  • 難しい患者集団をターゲットに
  • 新興市場

第6章 市場成長推進因子・阻害因子・代替品

  • 市場促進要因
  • 市場の障壁
  • 代替品

第7章 競合評価

  • 概要
  • 冠動脈ステント技術の開発動向
    • ベアメタルステント
    • 薬剤溶出性ステント
    • 生分解性ステント
    • カバー付きステント
  • 企業の市場シェア:世界
    • ベアメタルステント
    • 薬剤溶出性ステント
  • 企業の市場シェア:地域
    • ブラジル

第8章 パイプライン製品

  • 概要
  • 開発段階別パイプライン
  • パイプライン製品のプロファイル
    • 生体吸収性ステント
    • その他

第9章 臨床試験の分析

  • 概要
  • 注目の臨床試験

第10章 現在・将来の企業

  • 概要
  • 企業戦略の動向
  • 企業プロファイル
    • Abbott Vascular
    • Boston Scientific Corporation
    • Medtronic
    • Alvimedica
    • Amaranth Medical
    • amg International
    • Arterial Remodeling Technologies
    • B. Braun
    • Balton
    • Biosensors International
    • Biotronik
    • Blue Medical
    • Cardionovum
    • C.R. Bard
    • Elixir Medical Corporation
    • eucatech AG
    • Hexacath
    • IRAMED
    • JW Medical Systems
    • Kyoto Medical Planning
    • Lepu Medical Technology
    • MicroPort Scientific Corporation
    • Minvasys
    • MIV Therapeutics
    • Opto Circuits
    • OrbusNeich Medical
    • Relisys Medical Devices
    • REVA Medical
    • Sahajanand Medical Technologies
    • STENTYS
    • テルモ
    • Translumina
    • Vascular Concepts
    • その他

第11章 市場の見通し

  • 市場区分別
    • 概要
    • 薬剤溶出性ステント
    • ベアメタルステント
    • 新しいステント技術
  • 適応症別
  • 地域別
    • ブラジル

第12章 付録

図表

目次
Product Code: GDME1132CFR

The global coronary stents market is a dynamic, double-digit market that is saturated with numerous players developing innovative technologies. Rapid advances in the field of interventional cardiology along with the development of minimally invasive techniques have greatly expanded the potential of therapeutic applications. Coronary stents including bare metal, drug-eluting, covered and bioabsorbable stents can be used to treat coronary artery disease, and optimize outcomes.

Minimally-invasive techniques such as stenting have been widely adopted in Brazil. The coronary stents market will be driven by the rising prevalence of CAD, the growing aging population, and the potential cost savings associated with DES technologies.

Scope

  • An overview of Coronary Stents, which includes epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines.
  • Annualized the SA Coronary Stents market revenue and future forecasts from 2011 to 2013, forecast for 7 years to 2020.
  • Investigation of current and future market competition for Coronary Stents.
  • Insightful review of the key industry drivers, restraints and challenges as well as predicted impact of key events.
  • Competitor assessment including device approval analysis and device sales forecasts.
  • Marketed and pipeline product profiles covering efficiency, safety, clinical study details, device approvals, product positioning and device sales forecast.
  • Analysis of unmet needs within the market and opportunities for future players.
  • Technology trends evaluation to assess strength of pipeline.
  • An overview of all devices in development including clinical study details, design and material selection considerations, efficacy reports, and device approval timelines.
  • Company profiles including business description, financial overview and SWOT analysis.
  • Coverage of key market players.
  • Strategic assessment of the Coronary Stents sector through market impact analysis, future market scenario and company analysis.
  • Direct quotes from Key Opinion Leaders (KOL) as well as doctors

Reasons to buy

  • Understand the trends shaping and driving the SA Coronary Stents market.
  • Realize device preferences of physicians who have performed the tests already.
  • Access market sizing, forecasts and quantified growth opportunities in the SA Coronary Stents market through 2018.
  • Quantify candidate patient populations to better design product pricing & launch plans.
  • Drive revenues, formulate effective sales and marketing strategies and gain in-depth understanding of the competitive landscape.
  • Perform benchmarking analysis of growth opportunities against currently marketed products.
  • Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
  • Take a comprehensive look at the market's device pipeline and identify promising, paradigm-shifting products.
  • Create an effective counter-strategy to gain a competitive advantage against those currently in the market.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for growth.
  • What's the next big thing in the SA Coronary Stents market landscape? Identify, understand and capitalize.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports

3. Industry Overview

  • 3.1. Disease Overview
  • 3.2. Clinical Outcomes
    • 3.2.1. Treatment Guidelines
    • 3.2.2. Treatment Modalities
  • 3.3. Procedure Trends
    • 3.3.1. Brazil
  • 3.4. Market Access
    • 3.4.1. Regulatory Process
    • 3.4.2. Physician Decision-Making Process
    • 3.4.3. Role of Group Purchasing Organizations
    • 3.4.4. Lack of Clinical Data
    • 3.4.5. Regional-Level Control
    • 3.4.6. Cost Considerations
    • 3.4.7. Reimbursement Trends
  • 3.5. Regulatory Issues/Recalls
    • 3.5.1. Regulatory Issues
    • 3.5.2. Product Recalls
  • 3.6. Mergers and Acquisitions/ Key Partnerships
    • 3.6.1. Medtronic and Covidien
    • 3.6.2. Arterial Remodeling Technologies and Terumo Corporation
    • 3.6.3. MicroPort Scientific Corporation and Cordis Corporation
    • 3.6.4. Alvimedica and CID
    • 3.6.5. ITGI Medical and Vascular Solutions
    • 3.6.6. Terumo Corporation and Onset Medical Corporation
    • 3.6.7. Atrium Medical and Getinge Group
    • 3.6.8. C.R. Bard and ClearStream Technologies
    • 3.6.9. Biosensors International and Devax, CardioMind, and JW Medical Systems
    • 3.6.10. CeloNova Biosciences and Nexeon MedSystems
    • 3.6.11. Medtronic and Invatec
    • 3.6.12. Micell Technologies and Maxcor Lifescience
    • 3.6.13. Boston Scientific Corporation and Guidant Corporation
    • 3.6.14. Abbott Vascular and Guidant Corporation
    • 3.6.15. Kaneka Corporation and Fujisawa Pharmaceuticals
  • 3.7. Economic Impact of Coronary Artery Disease
    • 3.7.1. Brazil
  • 3.8. Treatment Costs for Coronary Artery Disease

4. Unmet Needs

  • 4.1. Need for Better Clinical Outcomes in Specific Lesions
    • 4.1.1. Chronic Total Occlusions
    • 4.1.2. Small-Vessel Coronary Lesions
    • 4.1.3. Heavily-Calcified and Uncrossable/Undilatable Lesions
    • 4.1.4. Bifurcation Lesions
    • 4.1.5. Saphenous Vein Graft Intervention
  • 4.2. Eliminating Mechanisms of Failure With Balloon Angioplasty
  • 4.3. Late Myocardial Infarction After Stenting
  • 4.4. Eliminating the Permanent Polymer
  • 4.5. In-Stent Restenosis
  • 4.6. Stent-In-Stent Procedures
  • 4.7. Prolonged Dual Antiplatelet Therapy
  • 4.8. Lack of Homogenous Drug Distribution
  • 4.9. Delayed Stent Endothelialization
  • 4.10. Negative Vessel Remodeling
  • 4.11. Need for Effective Therapy for Specific Patient Populations
  • 4.12. Addressing the Complications of Coronary Artery Bypass Grafting

5. Market Opportunity Analysis

  • 5.1. Improve Stent Design/Platform
    • 5.1.1. Stent Coating Technology
    • 5.1.2. Bioabsorbable Stent Technology
    • 5.1.3. Antiproliferative Drug and Elution Kinetics
  • 5.2. Hybrid Stent Systems
  • 5.3. Effective Therapies for Challenging Coronary Indications
    • 5.3.1. Chronic Total Occlusions
    • 5.3.2. Small-Vessel Disease
    • 5.3.3. Bifurcation Lesions
    • 5.3.4. Diffuse Atherosclerotic Disease
    • 5.3.5. Saphenous Vein Graft Intervention
    • 5.3.6. Acute Myocardial Infarction
  • 5.4. Target Challenging Patient Populations
  • 5.5. Emerging Markets

6. Market Drivers, Barriers, and Substitutes

  • 6.1. Market Drivers
    • 6.1.1. Rising Prevalence of Disease
    • 6.1.2. Viable Treatment for Challenging Coronary Indications
    • 6.1.3. Innovations in Stent Technology
    • 6.1.4. Development of Bioabsorbable Stents
    • 6.1.5. Reduce the Need for Prolonged Dual Antiplatelet Therapy
    • 6.1.6. Potential Cost Savings
    • 6.1.7. Use of Imaging Modalities for Accurate Stent Placement
    • 6.1.8. Adoption of Stents in the Emerging Markets
    • 6.1.9. Launch of Bioabsorbable Stents in US and Japan
  • 6.2. Market Barriers
    • 6.2.1. Concerns Regarding Overstenting
    • 6.2.2. Post-ProceduraI Complications of Drug-Eluting Stenting
    • 6.2.3. Risk of Perioperative Adverse Cardiac Events Post-Stenting
    • 6.2.4. Slow Adoption of Bioabsorbable Stents
    • 6.2.5. Lack of Reimbursement
    • 6.2.6. Healthcare Cost-Cutting and Reimbursement
    • 6.2.7. Availability of Venture Capital
    • 6.2.8. Medical Device Excise Tax
  • 6.3. Market Substitutes
    • 6.3.1. Drug-Eluting Balloons
    • 6.3.2. Liquid Drug Delivery Catheter

7. Competitive Assessment

  • 7.1. Overview
  • 7.2. Trends in Coronary Stent Technology Development
    • 7.2.1. Development of Bare Metal Stents
    • 7.2.2. Development of Drug-Eluting Stents
    • 7.2.3. Development of Bioabsorbable Stents
    • 7.2.4. Development of Covered Stents

7.2.5. Coronary Stent Technology SWOT Analysis

  • 7.3. Global Company Market Share
    • 7.3.1. Bare Metal Stent Market Share
    • 7.3.2. Drug-Eluting Stent Market Share
  • 7.4. Regional Company Market Share
    • 7.4.1. Brazil Market Share

8. Pipeline Products

  • 8.1. Overview
  • 8.2. Pipeline by Stage of Development
  • 8.3. Pipeline Product Profiles
    • 8.3.1. Bioabsorbable Stents
    • 8.3.2. Other Types of Vascular Stents

9. Clinical Trial Analysis

  • 9.1. Overview
  • 9.2. Clinical Trials to Watch
    • 9.2.1. Evaluating the Latest and New Generation of Drug-Eluting Stents
    • 9.2.2. Bioabsorbable Stent Clinical Trials
    • 9.2.3. Evaluating Stenting in Challenging Coronary Indications/Patient Populations
    • 9.2.4. Targeting Patient Populations in the APAC Region

10. Current and Future Players

  • 10.1. Overview
  • 10.2. Trends in Corporate Strategy
  • 10.3. Company Profiles
    • 10.3.1. Abbott Vascular
    • 10.3.2. Boston Scientific Corporation
    • 10.3.3. Medtronic
    • 10.3.4. Alvimedica
    • 10.3.5. Amaranth Medical
    • 10.3.6. amg International
    • 10.3.7. Arterial Remodeling Technologies
    • 10.3.8. B. Braun
    • 10.3.9. Balton
    • 10.3.10. Biosensors International
    • 10.3.11. Biotronik
    • 10.3.12. Blue Medical
    • 10.3.13. Cardionovum
    • 10.3.14. C.R. Bard
    • 10.3.15. Elixir Medical Corporation
    • 10.3.16. eucatech AG
    • 10.3.17. Hexacath
    • 10.3.18. IRAMED
    • 10.3.19. JW Medical Systems
    • 10.3.20. Kyoto Medical Planning
    • 10.3.21. Lepu Medical Technology
    • 10.3.22. MicroPort Scientific Corporation
    • 10.3.23. Minvasys
    • 10.3.24. MIV Therapeutics
    • 10.3.25. Opto Circuits
    • 10.3.26. OrbusNeich Medical
    • 10.3.27. Relisys Medical Devices
    • 10.3.28. REVA Medical
    • 10.3.29. Sahajanand Medical Technologies
    • 10.3.30. STENTYS
    • 10.3.31. Terumo Corporation
    • 10.3.32. Translumina
    • 10.3.33. Vascular Concepts
    • 10.3.34. Other Companies

11. Market Outlook

  • 11.1. By Market Segment
    • 11.1.1. Overview
    • 11.1.2. Drug-Eluting Stent Market
    • 11.1.3. Bare Metal Stent Market
    • 11.1.4. Emerging Stent Technologies
  • 11.2. By Indication
  • 11.3. By Geography
    • 11.3.1. Brazil

12. Appendix

  • 12.1. Bibliography
  • 12.2. Abbreviations
  • 12.3. Report Methodology
    • 12.3.1. Overview
    • 12.3.2. Coverage
    • 12.3.3. Secondary Research
  • 12.4. Physicians and Specialists Included in This Study
    • 12.4.1. Praveen Chandra, MD, DM, FESC, FSCAI, FAPSCI
    • 12.4.2. Bernado Cortese, MD, FESC
    • 12.4.3. Ricardo A. Costa, MD
    • 12.4.4. Thomas Cuisset, MD, PhD, FESC
    • 12.4.5. Nobuyuki Komiyama, MD, PhD, FACC, FJCC
    • 12.4.6. Roger J. Laham, MD
    • 12.4.7. Mark W. Mewissen, MD
    • 12.4.8. Gary S. Mintz, MD
    • 12.4.9. Tudor C. Poerner, MD
    • 12.4.10. David Ramsdale, MD, PhD
    • 12.4.11. Gregory A. Sgueglia, MD, PhD
    • 12.4.12. Madhukar Shahi, MD
    • 12.4.13. Takehiro Yamashita, MD, PhD, FACC
  • 12.5. Primary Research
    • 12.5.1. Primary Research - Key Opinion Leader Interviews
    • 12.5.2. Primary Research Interviews- Physician and Industry Participants
    • 12.5.3. Physican Survey
    • 12.5.4. Expert Panel Validation
  • 12.6. Forecasting Methodology
  • 12.7. About the Authors
    • 12.7.1. Analysts
    • 12.7.2. Global Head of Healthcare
  • 12.8. About MediPoint
  • 12.9. About GlobalData
  • 12.10. Disclaimer

List of Tables

  • Table 1: ACCF/AHA Treatment Guidelines to Improve the Symptoms of CAD*
  • Table 2: Types of CABG
  • Table 3: Complications of CABG
  • Table 4: Drugs Incorporated Into DES
  • Table 5: Types of Lesions Treated Using Atherectomy
  • Table 6: GPOs in the US and EU
  • Table 7: Direct and Indirect Healthcare Costs of CAD
  • Table 8: US Mean Hospital Costs* ($US) for Cardiac Revascularization Procedures, 2011-2020
  • Table 9: Coronary Stent Technology SWOT Analysis, 2014
  • Table 10: Global Coronary Stent Pipeline Products, 2014
  • Table 11: ART18Z SWOT Analysis, 2014
  • Table 12: DREAMS SWOT Analysis, 2014
  • Table 13: Fantom SWOT Analysis, 2014
  • Table 14: Fortitude SWOT Analysis, 2014
  • Table 15: Ideal BioStent SWOT Analysis, 2014
  • Table 16: Igaki-Tamai Stent SWOT Analysis, 2014
  • Table 17: ON-AVS SWOT Analysis, 2014
  • Table 18: Other Companies Developing BAS, 2014
  • Table 19: FOCUS np Eluting Stent SWOT Analysis, 2014
  • Table 20: STENTYS Sirolimus-Eluting Stent SWOT Analysis, 2014
  • Table 21: Svelte Drug-Eluting Stent SWOT Analysis, 2014
  • Table 22: Clinical Trials Evaluating the Latest and New Generation of DES, 2014
  • Table 23: Clinical Trials Evaluating Stenting in Challenging CAD Indications/Patient Populations, 2014
  • Table 24: Clinical Trials Evaluating Coronary Stenting in APAC Patient Populations, 2014
  • Table 25: Abbott Vascular Company Profile
  • Table 26: Abbott Vascular Coronary Stent Marketed Products
  • Table 27: Abbott Vascular Coronary Stent Product Portfolio SWOT Analysis, 2014
  • Table 28: Abbott Vascular SWOT Analysis, 2014
  • Table 29: Boston Scientific Corporation Company Profile
  • Table 30: Boston Scientific Coronary Stent Marketed Products
  • Table 31: Boston Scientific Coronary Stent Product Portfolio SWOT Analysis, 2014
  • Table 32: Boston Scientific Corporation SWOT Analysis, 2014
  • Table 33: Medtronic Company Profile
  • Table 34: Medtronic Coronary Stent Marketed Products
  • Table 35: Medtronic Coronary Stent Product Portfolio SWOT Analysis, 2014
  • Table 36: Medtronic SWOT Analysis, 2014
  • Table 37: Alvimedica Company Profile
  • Table 38: Alvimedica Coronary Stent Marketed Products
  • Table 39: Alvimedica Coronary Stent Product Portfolio SWOT Analysis, 2014
  • Table 40: Alvimedica SWOT Analysis, 2014
  • Table 41: Amaranth Medical Company Profile
  • Table 42: Amaranth Medical Coronary Stent Pipeline Product
  • Table 43: Amaranth Medical Coronary Stent Product Portfolio SWOT Analysis, 2014
  • Table 44: Amaranth Medical SWOT Analysis, 2014
  • Table 45: amg International Company Profile
  • Table 46: amg International Coronary Stent Marketed Products
  • Table 47: amg International Coronary Stent Product Portfolio SWOT Analysis, 2014
  • Table 48: amg International SWOT Analysis, 2014
  • Table 49: Arterial Remodeling Technologies Company Profile
  • Table 50: Arterial Remodeling Technologies Coronary Stent Pipeline Product
  • Table 51: Arterial Remodeling Technologies Coronary Stent Product Portfolio SWOT Analysis, 2014
  • Table 52: Arterial Remodeling Technologies SWOT Analysis, 2014
  • Table 53: B. Braun Company Profile
  • Table 54: B. Braun Coronary Stent Marketed Products
  • Table 55: B. Braun Coronary Stent Product Portfolio SWOT Analysis, 2014
  • Table 56: B. Braun SWOT Analysis, 2014
  • Table 57: Balton Company Profile
  • Table 58: Balton Coronary Stent Marketed Products
  • Table 59: BALTON Coronary Stent Product Portfolio SWOT Analysis, 2014
  • Table 60: Balton SWOT Analysis, 2014
  • Table 61: Biosensors International Company Profile
  • Table 62: Biosensors International Coronary Stent Marketed Products
  • Table 63: Biosensors International Coronary Stent Product Portfolio SWOT Analysis, 2014
  • Table 64: Biosensors International SWOT Analysis, 2014
  • Table 65: Biotronik Company Profile
  • Table 66: Biotronik Coronary Stent Marketed and Pipeline Products
  • Table 67: Biotronik Coronary Stent Product Portfolio SWOT Analysis, 2014
  • Table 68: Biotronik SWOT Analysis, 2014
  • Table 69: Blue Medical Company Profile
  • Table 70: Blue Medical Coronary Stent Marketed Products
  • Table 71: Blue Medical Coronary Stent Product Portfolio SWOT Analysis, 2014
  • Table 72: Blue Medical SWOT Analysis, 2014
  • Table 73: Cardionovum Company Profile
  • Table 74: Cardionovum Coronary Stent Marketed and Pipeline Products
  • Table 75: Cardionovum Coronary Stent Product Portfolio SWOT Analysis, 2014
  • Table 76: Cardionovum SWOT Analysis, 2014
  • Table 77: C.R. Bard Company Profile
  • Table 78: ClearStream Technologies Coronary Stent Marketed Products
  • Table 79: C.R. Bard Coronary Stent Product Portfolio SWOT Analysis, 2014
  • Table 80: C.R. Bard SWOT Analysis, 2014
  • Table 81: Elixir Medical Corporation Company Profile
  • Table 82: Elixir Medical Corporation Coronary Stent Marketed Products
  • Table 83: Elixir Medical Corporation Coronary Stent Product Portfolio SWOT Analysis, 2014
  • Table 84: Elixir Medical Corporation SWOT Analysis, 2014
  • Table 85: eucatech Profile
  • Table 86: eucatech Coronary Stent Marketed Products
  • Table 87: eucatech Coronary Stent Product Portfolio SWOT Analysis, 2014
  • Table 88: eucatech SWOT Analysis, 2014
  • Table 89: Hexacath Company Profile
  • Table 90: Hexacath Coronary Stent Marketed Products
  • Table 91: Hexacath Coronary Stent Product Portfolio SWOT Analysis, 2014
  • Table 92: Hexacath SWOT Analysis, 2014
  • Table 93: IRAMED Company Profile
  • Table 94: IRAMED Coronary Stent Marketed Products
  • Table 95: IRAMED Coronary Stent Product Portfolio SWOT Analysis, 2014
  • Table 96: IRAMED SWOT Analysis, 2014
  • Table 97: JW Medical Systems Company Profile
  • Table 98: JW Medical Systems Coronary Stent Marketed Product
  • Table 99: JW Medical Systems' Coronary Stent Product Portfolio SWOT Analysis, 2014
  • Table 100: JW Medical Systems SWOT Analysis, 2014
  • Table 101: Kyoto Medical Planning Company Profile
  • Table 102: Kyoto Medical Planning Coronary Stent Pipeline Product
  • Table 103: Kyoto Medical Planning Coronary Stent Product Portfolio SWOT Analysis, 2014
  • Table 104: Kyoto Medical Planning SWOT Analysis, 2014
  • Table 105: Lepu Medical Technology Company Profile
  • Table 106: Lepu Medical Technology Coronary Stent Marketed and Pipeline Products
  • Table 107: Lepu Medical Technology Coronary Stent Product Portfolio SWOT Analysis, 2014
  • Table 108: Lepu Medical Technology SWOT Analysis, 2014
  • Table 109: MicroPort Scientific Corporation Company Profile
  • Table 110: MicroPort Scientific Corporation Coronary Stent Marketed Products
  • Table 111: MicroPort Scientific Corporation Coronary Stent Product Portfolio SWOT Analysis, 2014
  • Table 112: MicroPort Scientific Corporation SWOT Analysis, 2014
  • Table 113: Minvasys Company Profile
  • Table 114: Minvasys Coronary Stent Marketed and Pipeline Products
  • Table 115: Minvasys Coronary Stent Product Portfolio SWOT Analysis, 2014
  • Table 116: Minvasys SWOT Analysis, 2014
  • Table 117: MIV Therapeutics Company Profile
  • Table 118: MIV Therapeutics Coronary Stent Marketed Products
  • Table 119: MIV Therapeutics Coronary Stent Product Portfolio SWOT Analysis, 2014
  • Table 120: MIV Therapeutics SWOT Analysis, 2014
  • Table 121: Opto Circuits Company Profile
  • Table 122: Opto Circuits Coronary Stent Marketed Products
  • Table 123: Opto Circuits Coronary Stent Product Portfolio SWOT Analysis, 2014
  • Table 124: Opto Circuits SWOT Analysis, 2014
  • Table 125: OrbusNeich Medical Company Profile
  • Table 126: OrbusNeich Medical Coronary Stent Marketed and Pipeline Products
  • Table 127: OrbusNeich Medical Coronary Stent Product Portfolio SWOT Analysis, 2014
  • Table 128: OrbusNeich Medical SWOT Analysis, 2014
  • Table 129: Relisys Medical Devices Company Profile
  • Table 130: Relisys Medical Devices Coronary Stent Marketed Products
  • Table 131: Relisys Medical Devices Coronary Stent Product Portfolio SWOT Analysis, 2014
  • Table 132: Relisys Medical Devices SWOT Analysis, 2014
  • Table 133: REVA Medical Company Profile
  • Table 134: REVA Medical Coronary Stent Pipeline Product
  • Table 135: REVA Medical Coronary Stent Product Portfolio SWOT Analysis, 2014
  • Table 136: REVA Medical SWOT Analysis, 2014
  • Table 137: Sahajanand Medical Technologies Company Profile
  • Table 138: Sahajanand Medical Technologies Coronary Stent Marketed and Pipeline Products
  • Table 139: Sahajanand Medical Technologies Coronary Stent Product Portfolio SWOT Analysis, 2014
  • Table 140: Sahajanand Medical Technologies SWOT Analysis, 2014
  • Table 141: STENTYS Company Profile
  • Table 142: STENTYS Coronary Stent Marketed and Pipeline Products
  • Table 143: STENTYS Coronary Stent Product Portfolio SWOT Analysis, 2014
  • Table 144: STENTYS SWOT Analysis, 2014
  • Table 145: Terumo Corporation Company Profile
  • Table 146: Terumo Corporation Coronary Stent Marketed and Pipeline Products
  • Table 147: Terumo Corporation Coronary Stent Product Portfolio SWOT Analysis, 2014
  • Table 148: Terumo Corporation SWOT Analysis, 2014
  • Table 149: Translumina Company Profile
  • Table 150: Translumina Coronary Stent Marketed Products
  • Table 151: Translumina Coronary Stent Product Portfolio SWOT Analysis, 2014
  • Table 152: Translumina SWOT Analysis, 2014
  • Table 153: Vascular Concepts Company Profile
  • Table 154: Vascular Concepts Coronary Stent Marketed Products
  • Table 155: Vascular Concepts Coronary Stent Product Portfolio SWOT Analysis, 2014
  • Table 156: Vascular Concepts SWOT Analysis, 2014
  • Table 157: Other Companies in the Coronary Stent Market, North America, 2014
  • Table 158: Other Companies in the Coronary Stent Market, EU, 2014
  • Table 159: Other Companies in the Coronary Stent Market, APAC, 2014
  • Table 160: Other Companies in the Coronary Stent Market, South Africa and South America, 2014
  • Table 161: Global Coronary Stent Sales ($m) Forecast, by Segment, 2011-2020
  • Table 162: Global DES Sales ($m) Forecast, 2011-2020
  • Table 163: Global BMS Sales ($m) Forecast, 2011-2020
  • Table 164: Coronary Stents Market Sales ($m) Forecast for Brazil, 2011-2020
  • Table 165: Primary Research Interviews Completed
  • Table 166: Physicians Surveyed, By Country

List of Figures

  • Figure 1: Pathophysiology of CAD
  • Figure 2: CAD Treatment Modalities
  • Figure 3: Percentage of Patients with CAD Who Receive Each Therapy Option Only, Global, 2012 and 2019 (N=58)
  • Figure 4: Percentage of Patients with CAD Who Receive Each Type of PCI Only, Global, 2012 and 2019 (N=58)
  • Figure 5: Types of Stents Used to Treat CAD
  • Figure 6: Example of a BMS
  • Figure 7: Example of a DEB
  • Figure 8: Types of Atherectomy
  • Figure 9: Global Coronary Stenting Procedure Volume, 2011-2020
  • Figure 10: Brazil Coronary Stenting Procedure Volume, 2011-2020
  • Figure 11: US Mean Hospital Costs* ($US) for Cardiac Revascularization Procedures, 2011-2020
  • Figure 12: Percentage of CAD Patients with ISR, Global, 2012 and 2018 (N=58)
  • Figure 13: Percentage of CAD Patients Who Receive Stent-In-Stent Procedures, Global, 2012 and 2018 (N=58)
  • Figure 14: Interventional Cardiologists' Ranking of the Importance of Each Therapy Attribute in Adopting Stents for the Treatment of CAD, Global, 2013 (N=101)
  • Figure 15: Global Coronary Stents Market Value Share (%), 2013 and 2020
  • Figure 16: Global BMS Company Market Share (%), 2013
  • Figure 17: Global DES Company Market Share (%), 2013
  • Figure 18: Brazil Market Share for BMS (%), 2013
  • Figure 19: Brazil Market Share for DES (%), 2013
  • Figure 20: Global Coronary Stent Pipeline Products by Stage of Development, 2014
  • Figure 21: Global Coronary Stents Market Revenue ($m), 2011-2020
  • Figure 22: Global DES Market Revenue ($m), 2011-2020
  • Figure 23: Global BMS Market Revenue ($m), 2011-2020
  • Figure 24: Percentage of Patients (%) Treated with Each Type of Coronary Stent Only, Global, 2013 and 2020 (N=101)
  • Figure 25: Percentage of Patients (%) Treated with Coronary Stents for Each Indication, Global, 2013 and 2020 (N=101)
  • Figure 26: Brazilian Sales ($m) Forecast for Coronary Stents, 2011-2020
Back to Top